HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maria B Zalath Selected Research

C 39 (C39)

10/2020Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Maria B Zalath Research Topics

Disease

2Neoplasms (Cancer)
10/2020 - 01/2018
1Triple Negative Breast Neoplasms
10/2020
1Multiple Myeloma
01/2018
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2018
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2018
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2018
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2018
1Melanoma (Melanoma, Malignant)
01/2018
1Body Weight (Weight, Body)
01/2018
1Hodgkin Disease (Hodgkin's Disease)
01/2018

Drug/Important Bio-Agent (IBA)

2Irinotecan (Camptosar)FDA LinkGeneric
10/2020 - 01/2018
1sacituzumab govitecanIBA
10/2020
1Biomarkers (Surrogate Marker)IBA
10/2020
1DNA (Deoxyribonucleic Acid)IBA
10/2020
1C 39 (C39)IBA
10/2020
1Immunoconjugates (Immunoconjugate)IBA
01/2018
1IMMU-114IBA
01/2018
1Histocompatibility Antigens Class IIIBA
01/2018
1HLA-DR Antigens (HLA-DR)IBA
01/2018
1Pharmaceutical PreparationsIBA
01/2018

Therapy/Procedure

1Therapeutics
01/2018